Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Research & Development (2016 - 2025)

Historic Research & Development for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $2.6 million.

  • Champions Oncology's Research & Development rose 5488.45% to $2.6 million in Q4 2025 from the same period last year, while for Oct 2025 it was $8.4 million, marking a year-over-year increase of 1356.55%. This contributed to the annual value of $6.8 million for FY2025, which is 2848.91% down from last year.
  • Per Champions Oncology's latest filing, its Research & Development stood at $2.6 million for Q4 2025, which was up 5488.45% from $2.1 million recorded in Q3 2025.
  • Over the past 5 years, Champions Oncology's Research & Development peaked at $3.2 million during Q1 2023, and registered a low of $1.5 million during Q3 2024.
  • For the 5-year period, Champions Oncology's Research & Development averaged around $2.3 million, with its median value being $2.2 million (2021).
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 4794.13% in 2024, then soared by 5488.45% in 2025.
  • Over the past 5 years, Champions Oncology's Research & Development (Quarter) stood at $2.3 million in 2021, then increased by 13.27% to $2.6 million in 2022, then decreased by 3.42% to $2.5 million in 2023, then crashed by 32.84% to $1.7 million in 2024, then surged by 54.88% to $2.6 million in 2025.
  • Its Research & Development was $2.6 million in Q4 2025, compared to $2.1 million in Q3 2025 and $2.0 million in Q2 2025.